3Spiegelman BM.PPAR gamma:adipogenic regulator and thiazolldlnedone receptor.Diabetes 1998;47:507-514.
4Lebovitz HE,Dole JF,Patwardhan R,et al.Rceiglitazone monotherapy is effective in patients with type 2 diabetes.J Clin Endocrinol Metsb 2001;86:280-288.
二级参考文献10
1Purrello F, Rabuazza AM. Metabolic factors that affect betacell function and survival. Diabet Nutr Metab, 2000, 13: 84-91.
2Sivitz WI. Lipotoxieity and glueotoxieity in type 2 diabetes. Effects on development and progression. Postgrad Med, 2001,109: 55-59,63-64.
3Lenhard M J, Reeves GD. Continous subcutaneous insulin infusion: a comprehensive review of insulin pump therapy. Arch Intern Med,2001,161: 2293-2300.
4Dupuy O, Mayaudon H, Palou M, et al. Optimized transient insulin infusion in uneontrolled type 2 Diabetes : Evaluation of a pragmatie attitude. Diabet Med, 2000,26 : 371-375.
5Valensi P, Moura I, Magoarou M,et al. Short-term effects of continuous subcutaneous insulin infusion treatment on insulin secretion in non-insulin-dependent overweight patients with poor glycaemic control despite maximal oral anti-diabetic treatment. Diabet Metab,1997,23: 51-57.
6Lormeau B, Aurousseau MH, Valensi P, et al. Hyperinsulinemia and hypofibrinolysis: effects of short-term optimized glyeemic control with contineuous insulin infusion in type Ⅱ diabetie patients. Metabolism,1997,46: 1074-1079.
7Ilkova H, Glaser B, Tunckale A, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care, 1997,20:1353-1356.
8Pratley RE, Weyer C. The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus. Diabetologia 2001,44:929-945.
9Del Prato S, Marchetti P, Bonadonna RC. Phasic insulin release and metabolic regulation in type 2 diabetes. Diabetes,2002, 51suppl 1: s109-116.
10Kahn SE. The importance of the beta-cell in the pathogenesis of type 2 diabetes mellitus. Am J Med, 2000,108suppl 6a: 2s-8s.
